Malaria: prevention in travellers


Malaria is an acute parasitic disease of the tropics and subtropics, caused by the invasion and destruction of red blood cells by one or more of four species of the genus Plasmodium: P falciparum,P vivax,P ovale, and P malariae.[1] The clinical presentation of malaria varies according to the infecting species, and according to the genetics, immune status, and age of the infected person.[2] The most severe form of human malaria is caused by P falciparum, in which variable clinical features include spiking fevers, chills, headache, muscular aching and weakness, vomiting, cough, diarrhoea, and abdominal pain; other symptoms related to organ failure may supervene, such as acute renal failure, generalised convulsions, and circulatory collapse, followed by coma and death.[3][4]P falciparum accounts for greater than 50% of malaria infections in most East Asian countries, greater than 90% in sub-Saharan Africa, and almost 100% in Hispaniola.[5] Travellers are defined here as visitors from a malaria-free area to a malaria-endemic area, who stay in the endemic area for less than 1 year.

Latest citations

Mass drug administration for malaria. (07 January 2014)

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. (12 December 2013)